Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-5960
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis ; volume:7 ; number:1 ; day:10 ; month:4 ; year:2019 ; pages:1-19 ; date:12.2019
Acta Neuropathologica Communications ; 7, Heft 1 (10.4.2019), 1-19, 12.2019
- Urheber
-
Sundstrøm, Terje
Prestegarden, Lars
Azuaje, Francisco
Aasen, Synnøve Nymark
Røsland, Gro Vatne
Varughese, Jobin K.
Bahador, Marzieh
Bernatz, Simon
Braun, Yannick
Harter, Patrick Nikolaus
Skaftnesmo, Kai Ove
Ingham, Elizabeth S.
Mahakian, Lisa M.
Tam, Sarah
Tepper, Clifford G.
Petersen, Kjell
Ferrara, Katherine W.
Tronstad, Karl Johan
Lund-Johansen, Morten
Beschorner, Rudi
Bjerkvig, Rolf
Thorsen, Frits
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40478-019-0712-8
- URN
-
urn:nbn:de:101:1-2019042820073397519690
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sundstrøm, Terje
- Prestegarden, Lars
- Azuaje, Francisco
- Aasen, Synnøve Nymark
- Røsland, Gro Vatne
- Varughese, Jobin K.
- Bahador, Marzieh
- Bernatz, Simon
- Braun, Yannick
- Harter, Patrick Nikolaus
- Skaftnesmo, Kai Ove
- Ingham, Elizabeth S.
- Mahakian, Lisa M.
- Tam, Sarah
- Tepper, Clifford G.
- Petersen, Kjell
- Ferrara, Katherine W.
- Tronstad, Karl Johan
- Lund-Johansen, Morten
- Beschorner, Rudi
- Bjerkvig, Rolf
- Thorsen, Frits
- SpringerLink (Online service)
Ähnliche Objekte (12)
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma
ROCK 1 is a potential combinatorial drug target for BRAF mutant melanoma
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Paraneoplastic Cerebellar Degeneration Secondary to BRAF Mutant Melanoma Metastasis from an Occult Primary Cancer
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma
ROCK 1 is a potential combinatorial drug target for BRAF mutant melanoma
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Paraneoplastic Cerebellar Degeneration Secondary to BRAF Mutant Melanoma Metastasis from an Occult Primary Cancer
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma
ROCK 1 is a potential combinatorial drug target for BRAF mutant melanoma
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Paraneoplastic Cerebellar Degeneration Secondary to BRAF Mutant Melanoma Metastasis from an Occult Primary Cancer